Tag:
Prostvac
Latest Headlines
Latest Headlines
Bavarian Nordic starts PhII of Prostvac in early-stage cancer
Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.
Bristol-Myers bets $1B on Bavarian Nordic cancer vaccine
After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.
UPDATED: Bristol-Myers forges a billion-dollar cancer vaccine deal with Bavarian Nordic
Bristol-Myers Squibb has swooped in with $60 million upfront to gain an option on Bavarian Nordic's Phase III therapeutic prostate cancer vaccine Prostvac, ready to shell out an additional $915 million-plus in milestones if it takes the next step to license and ultimately commercialize the therapy.
Combo of Bavarian Nordic's Prostvac and BMS' Yervoy yields promising PhI results
On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.
Vax, hormone combo could up efficacy in prostate cancer
Prostate cancer could affect as many as one in 6 men during their lifetime, according to the U.S. National Cancer Institute, and for some their cancers recur and become hormone-resistant. The Cancer Institute of New Jersey and the National Cancer Institute have hooked up to see if combining a vaccine and hormone treatment will improve the response.
Prostate cancer vaccine teams up with antibody
Sometimes, the sum of the parts is greater than the whole, and this can be true for cancer therapies as well. Researchers are hoping that combining Prostvac, the investigational therapeutic cancer...
Bavarian Nordic gets good news on Prostvac
Danish biotech Bavarian Nordic saw its stock shoot up after the FDA approved a Phase III trial design for Prostvac, the company's prostate cancer vaccine. The company's stock rose as much as 6.5
Bavarian Nordic spotlights hopes for big cancer vax pact
Shares of Bavarian Nordic jumped seven percent after the Danish drug developer asserted that it is close to landing a big pharma partner for its closely watched prostate cancer vaccine, which is
